Clinical Psychiatry News - Rimonabant markedly improves cardiovascular risk profile.(Across Specialties)
NEW ORLEANS — Evidence is mounting that rimonabant, shown effective for weight loss and smoking cessation, independently improves patients’ cardiovascular risk profiles, F. Xavier Pi-Sunyer, M.D. reported at the annual scientific sessions of the American Heart Association.
In the wake of the highly favorable results that the Rimonabant in Obesity–North America (RIO-NA) trial presented, the company plans to file for marketing approval for the investigational drug in the second quarter of 2005, a Sanofi-Synthelabo spokesman told this newspaper.
Related Results
Cheyenne, Wyo.-area doctors skeptical of ’super bill’ for weight loss, smoking.
Pounds-off prescription
FDA Shouldn’t Approve Diet Drug, Panel Says
Pill could help obesity and smoking.(News)(Brief Article)
Shares in Sanofi fall after anti-obesity drug setback
A total of 3,040 obese patients …
Read the rest of this article with a Free Trial at HighBeam Research.
